Sanofi Pasteur Partners With VivalisFor The Discovery of Human MonoclonalAntibodies Against Infectious Diseases, Sanofi Pasteur MSD

Release Date: 2010-06-08

Lyon, France – June 8, 2010 - Sanofi Pasteur, the vaccines division of sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), announced today the signature with Vivalis (NYSE and Euronext: VLS) of a commercial license and collaboration agreement for the discovery and
development of fully human monoclonal antibodies against several infectious diseases.

Under the terms of the agreement, Sanofi Pasteur and its affiliates acquire exclusive access to Vivalis’ platform for the discovery of fully human monoclonal antibodies targeting clinically significant infectious diseases, and will obtain worldwide exclusive development and commercialization rights for the discovered antibodies.

“Passive immunization can be a powerful treatment option against infectious diseases in sometimes life threatening situations. Vivalis’ Humalex® technology allows rapid identification of clinically relevant fully human antibodies, as well as their related antigen. This opens up new medical solutions to prevent or treat serious infections,” said Michel de Wilde, Senior Vice President, Research and Development, Sanofi Pasteur. “We are pleased to team up with Vivalis to discover and develop new biologicals against infectious diseases for patients worldwide.”

"We are very excited about this collaboration with Sanofi Pasteur. This is the first major commercial agreement on the Humalex® platform but it also represents a strong validation of the technology. Vivalis is today one of a very few companies able to propose a fully integrated offering from the discovery of fully human monoclonal antibodies to the production of clinical batches. We are particularly proud to enter this new domain with a leader that has already heavily invested in the field”, said Franck Grimaud, Chief Executive Officer of Vivalis.

Vivalis will receive an upfront payment of 3 million euros, and may receive development milestone payments of up to 35 million euros over the course of the development of each infectious disease indication, as well as royalty payments associated with product sales. In addition, Sanofi Pasteur will finance agreed upon collaborative research activities related to the infectious diseases programs.

Type:	NORMAL
Company:	Sanofi Pasteur MSD
Country:	法国